Michael T. Yin

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Lihong Liu, Pengfei Wang, Manoj S. Nair et al. · Nature · 2020 · 1.6K citations · Full text

Pharmacy, Immunology, Infectious Diseases +14

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Lihong Liu, Sho Iketani, Yicheng Guo et al. · Nature · 2021 · 1.4K citations · Full text

Pharmacy, Immunology, Infectious Diseases +13

Antibody evasion properties of SARS-CoV-2 Omicron sublineages

Sho Iketani, Lihong Liu, Yicheng Guo et al. · Nature · 2022 · 857 citations · Full text

Life Sciences, Immunology, Infectious Diseases +16

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5

Qian Wang, Yicheng Guo, Sho Iketani et al. · Nature · 2022 · 844 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +13

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Paul E. Sax, David A. Wohl, Michael T. Yin et al. · The Lancet · 2015 · 598 citations

Pharmacy, Pharmacology, Pharmacotherapy +17